These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32845528)

  • 1. Sclerostin-Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters.
    Farrell M; Fairfield H; Costa S; D'Amico A; Falank C; Brooks DJ; Reagan MR
    J Bone Miner Res; 2021 Jan; 36(1):158-169. PubMed ID: 32845528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin antibody increases trabecular bone and bone mechanical properties by increasing osteoblast activity damaged by whole-body irradiation in mice.
    Costa S; Fairfield H; Farrell M; Murphy CS; Soucy A; Vary C; Holdsworth G; Reagan MR
    Bone; 2021 Jun; 147():115918. PubMed ID: 33737193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Lining Cells Could Be Sources of Bone Marrow Adipocytes.
    Lee JY; Yang JY; Kim SW
    Front Endocrinol (Lausanne); 2021; 12():766254. PubMed ID: 34925236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
    Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
    J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate restriction impairs mTORC1 signaling leading to increased bone marrow adipose tissue and decreased bone in growing mice.
    Ko FC; Kobelski MM; Zhang W; Grenga GM; Martins JS; Demay MB
    J Bone Miner Res; 2021 Aug; 36(8):1510-1520. PubMed ID: 33900666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X; Jee WS; Li X; Paszty C; Ke HZ
    Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
    Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
    J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
    Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
    Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis.
    McDonald MM; Morse A; Birke O; Yu NYC; Mikulec K; Peacock L; Schindeler A; Liu M; Ke HZ; Little DG
    J Orthop Res; 2018 Apr; 36(4):1106-1113. PubMed ID: 28884841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.
    Costa S; Fairfield H; Reagan MR
    Bone; 2019 Jun; 123():211-223. PubMed ID: 30954729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanically Driven Counter-Regulation of Cortical Bone Formation in Response to Sclerostin-Neutralizing Antibodies.
    Gerbaix M; Ammann P; Ferrari S
    J Bone Miner Res; 2021 Feb; 36(2):385-399. PubMed ID: 33049076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Hu R; Pacheco E; Locher K; Pyrah I; Ominsky MS; Boyce RW
    Bone Rep; 2018 Jun; 8():95-103. PubMed ID: 29955627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
    Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
    Front Genet; 2021; 12():705505. PubMed ID: 34447412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of PPARγ inhibition on bone marrow adipose tissue and bone in C3H/HeJ mice.
    Beekman KM; Veldhuis-Vlug AG; van der Veen A; den Heijer M; Maas M; Kerckhofs G; Parac-Vogt TN; Bisschop PH; Bravenboer N
    Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E96-E105. PubMed ID: 30457914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.